title: Effects of Flaxseed Lignan Secoisolariciresinol Diglucosideon Preneoplastic Biomarkers of Cancer Progression in a Model of Simultaneous Breast and Ovarian Cancer Development.
abstract: Breast cancer prevention efforts are focused increasingly on potentially beneficial dietary modifications due to their ease of implementation and wide acceptance. Secoisolariciresinol diglucoside (SDG) is a lignan found in high concentration in flaxseed that may have selective estrogen receptor modulator-like effects resulting in antiestrogenic activity in a high estrogen environment. In parallel with a human phase II prevention trial, female ACI rats (n = 8-10/group) received 0, 10, or 100 ppm SDG in the feed. The 100 ppm SDG treatment produced similar blood lignan levels as those observed in our human pilot study. Mammary and ovarian cancer progression were induced using local ovarian DMBA treatment and subcutaneous sustained release 17β-estradiol administered starting at 7 weeks of age. Mammary gland and ovarian tissues were collected at 3 mo after initiation of treatment and examined for changes in epithelial cell proliferation (Ki-67, cell counts), histopathology, and dysplasia scores, as well as expression of selected genes involved in proliferation, estrogen signaling, and cell adhesion. Treatment with SDG normalized several biomarkers in mammary gland tissue (dysplasia, cell number, and expression of several genes) that had been altered by carcinogen. There is no indication that SDG promotes preneoplastic progression in the ovarian epithelium.
authors.affiliation: a Breast Cancer Prevention Center, Department of Internal Medicine , University of Kansas Medical Center , Kansas City , Kansas , USA.
authors.forename: Devora M
authors.initials: DM
authors.lastname: Delman
authors.forename: Carol J
authors.initials: CJ
authors.lastname: Fabian
authors.forename: Bruce F
authors.initials: BF
authors.lastname: Kimler
authors.forename: Henry
authors.initials: H
authors.lastname: Yeh
authors.forename: Brian K
authors.initials: BK
authors.lastname: Petroff
mesh_terms: D000818:Animals; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D002072:Butylene Glycols / Q000494:pharmacology*; D002448:Cell Adhesion; D004195:Disease Models, Animal; D018450:Disease Progression; D004353:Drug Evaluation, Preclinical; D020847:Estrogen Receptor Modulators / Q000494:pharmacology; D005260:Female; D019597:Flax / Q000737:chemistry*; D005960:Glucosides / Q000494:pharmacology*; D019394:Ki-67 Antigen / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D048789:Phytoestrogens / Q000494:pharmacology*; D011230:Precancerous Conditions / Q000473:pathology; D051381:Rats; D011912:Rats, Inbred ACI; D012639:Seeds / Q000737:chemistry*
chemical_list: D014408:Biomarkers, Tumor; D002072:Butylene Glycols; D020847:Estrogen Receptor Modulators; D005960:Glucosides; D019394:Ki-67 Antigen; D048789:Phytoestrogens; C090142:secoisolariciresinol diglucoside